NEW YORK, February 17, 2017 /PRNewswire/ --
On Thursday, February 16, 2017, the NASDAQComposite and the S&P 500 edged lower at the closing bell, while the Dow Jones Industrial Average continued its bullish streak above the 20,000 benchmark. Moreover, five out of nine sectors ended Thursday's trading session in bearish territories.
Smith & Nephew
London, the UK headquartered Smith & Nephew PLC's stock finished Thursday's session 0.13% higher at $30.66 with a total volume of 584,897 shares traded. Over the last one month and the previous three months, Smith & Nephew's shares have advanced 0.95% and 11.49%, respectively. The Company's shares are trading above its 50-day moving average by 1.93%. Shares of Smith & Nephew, which develops, manufactures, markets, and sells medical technology products and services worldwide, are trading at a PE ratio of 17.45. Moreover, the stock has a Relative Strength Index (RSI) of 56.49.
On January 19th, 2017, research firm HSBC Securities initiated a 'Hold' rating on the Company's stock. See our free and comprehensive research report on SNN at:
Danvers, Massachusetts headquartered ABIOMED Inc.'s stock advanced 3.28%, to close the day at $114.25. The stock recorded a trading volume of 725,334 shares, which was above its three months average volume of 454,110 shares. ABIOMED's shares have gained 0.87% in the last one month, 2.38% in the previous three months, and 43.69% in the past one year. The Company's shares are trading 1.64% and 1.14% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart, are trading at a PE ratio of 106.48. Additionally, the stock has an RSI of 58.02. ABMD free research report PDF is just a click away at:
On Thursday, shares in Redwood City, California headquartered Nevro Corp. ended the session 0.11% lower at $93.95 with a total volume of 305,823 shares traded. Nevro's shares have advanced 5.42% in the last one month and 7.13% in the previous three months. Furthermore, the Company's stock has surged 71.07% in the past one year. The stock is trading 14.13% above its 50-day moving average and 11.96% above its 200-day moving average. Moreover, shares of the Company, which develops and commercializes a neuromodulation platform for the treatment of chronic pain in the US, Europe, and Australia, have an RSI of 72.55.
On January 30th, 2017, research firm Northland Capital upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. Sign up for your complimentary report on NVRO at:
On Thursday, shares in Leicester, the UK headquartered Steris PLC recorded a trading volume of 442,019 shares. The stock ended the day 0.41% lower at $68.44. Shares of the Company, which develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide, are trading at a PE ratio of 41.81. Steris' stock has advanced 2.72% in the last three months and 9.14% in the previous one year. The Company is trading below its 50-day and 200-day moving averages by 0.55% and 0.70%, respectively. Furthermore, Steris' shares have an RSI of 46.51. Register for free on Stock-Callers.com and download the latest research report on STE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All